Abstract
Autoimmune diseases affect approximately 6% of the population and are characterised by a pathogenic immune response that targets self-antigens. Well known diseases of this nature include type 1 diabetes, systemic lupus erythematosus, rheumatoid arthritis and multiple sclerosis. Treatment is often restricted to replacement therapy or immunosuppressive regimes and to date there are no cures. The strategy of utilising autologous or allogeneic haematopoietic stem cell transplantation to treat autoimmunity and induce immunological tolerance has been trailed with various levels of success. A major issue is disease relapse as the autoimmune response is reinitiated. Cells of the immune system originate from bone marrow and have a central role in the induction of immunological tolerance. The ability to isolate and genetically manipulate bone marrow haematopoietic stem cells therefore makes these cells a suitable vehicle for driving ectopic expression of defined autoantigens and induction of immunological tolerance.
Keywords: Haematopoietic stem cells, Gene therapy, Immunological tolerance, Autoimmunity
Current Stem Cell Research & Therapy
Title: Haematopoietic Stem Cell Gene Therapy to Treat Autoimmune Disease
Volume: 1 Issue: 3
Author(s): Frank Alderuccio, Christopher Siatskas, James Chan, Judith Field, Kim Murphy, Zeyad Nasa and Ban-Hock Toh
Affiliation:
Keywords: Haematopoietic stem cells, Gene therapy, Immunological tolerance, Autoimmunity
Abstract: Autoimmune diseases affect approximately 6% of the population and are characterised by a pathogenic immune response that targets self-antigens. Well known diseases of this nature include type 1 diabetes, systemic lupus erythematosus, rheumatoid arthritis and multiple sclerosis. Treatment is often restricted to replacement therapy or immunosuppressive regimes and to date there are no cures. The strategy of utilising autologous or allogeneic haematopoietic stem cell transplantation to treat autoimmunity and induce immunological tolerance has been trailed with various levels of success. A major issue is disease relapse as the autoimmune response is reinitiated. Cells of the immune system originate from bone marrow and have a central role in the induction of immunological tolerance. The ability to isolate and genetically manipulate bone marrow haematopoietic stem cells therefore makes these cells a suitable vehicle for driving ectopic expression of defined autoantigens and induction of immunological tolerance.
Export Options
About this article
Cite this article as:
Alderuccio Frank, Siatskas Christopher, Chan James, Field Judith, Murphy Kim, Nasa Zeyad and Toh Ban-Hock, Haematopoietic Stem Cell Gene Therapy to Treat Autoimmune Disease, Current Stem Cell Research & Therapy 2006; 1 (3) . https://dx.doi.org/10.2174/157488806778226885
DOI https://dx.doi.org/10.2174/157488806778226885 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
In Vitro Models of Human T Cell Development: Dishing Out Progenitor T Cells
Current Immunology Reviews (Discontinued) Structure-Activity Relationships of p38 Mitogen-Activated Protein Kinase Inhibitors
Mini-Reviews in Medicinal Chemistry Chemokines and Chemokine Receptors as Targets in the Therapy of Psoriasis
Current Drug Targets - Inflammation & Allergy Artemisinin, Promising Lead Natural Product for Various Drug Developments
Mini-Reviews in Medicinal Chemistry Therapeutic Potential of Hammerhead Ribozymes in the Treatment of Hyper-Proliferative Diseases
Current Pharmaceutical Biotechnology Kidney Diseases and Chemokines
Current Drug Targets Ethical and Social Issues in Pharmacogenomics Testing
Current Pharmaceutical Design A New Drug Candidate (GEMSP) for Multiple Sclerosis
Current Medicinal Chemistry Current Status and Future Prospects of Small–molecule Protein–protein Interaction (PPI) Inhibitors of Tumor Necrosis Factor (TNF) and Receptor Activator of NF-κB Ligand (RANKL)
Current Topics in Medicinal Chemistry Ghrelin and Motilin in the Gastrointestinal System
Current Pharmaceutical Design Editorial [Hot Topic: Gold Derivatives as Anti-Cancer Agents (Guest Editor: Laura Rodriguez Raurell)]
Anti-Cancer Agents in Medicinal Chemistry Statistical Molecular Design of Balanced Compound Libraries for QSAR Modeling
Current Medicinal Chemistry Using Biologic Agents in Pediatric Rheumatologic Diseases
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Editorial [Hot Topic: The Eye in Rheumatological Disease (Guest Editors: Sue Lightman and Simon Taylor)]
Current Rheumatology Reviews Hydroxychloroquine (HCQ) and its Synthetic Precursors: A Review
Mini-Reviews in Organic Chemistry Allergen-Induced Inflammation
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Recent Advances in Liposome Techniques and their Applications in Arthritis
Recent Patents on Biomedical Engineering (Discontinued) Nicotinamide Phosphoribosyltransferase (Nampt): A Link Between NAD Biology, Metabolism, and Diseases
Current Pharmaceutical Design Cytotoxicity and Anti-Inflammatory Effects of Polyherbal Formulations, Joint Pain Spl and Rumalaya Forte on Lipopolysaccharide Induced Inflammation in IC-21 Macrophages
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Subject Index to Volume 2
Current Drug Targets - Inflammation & Allergy